Compare Illumina, Inc. (ILMN) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs NetFlix Inc — how do they compare? Illumina, Inc. trades at $192.38 (market cap $29.12B), while NetFlix Inc trades at $74.2 (market cap $311.42B). The key difference: NetFlix Inc is far larger — about 10.7× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | NFLX | |
|---|---|---|
Market Cap | $29.12B | $311.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $205.10 | $126.33 |
52-Week Low | $91.00 | $67.60 |
Enterprise Value | $30.48B | $316.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $192.57, up 0.4% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.31 exceeding expectations. Revenue remains stable around $4.3B, and profitability has improved significantly, with a net income margin of 19.57% in 2025. The company maintains robust cash flow from operations of $1.08B in 2025.
The outlook is mixed; strong fundamentals and analyst buy ratings support upside to the $201.58 consensus target, but technical weakness and high valuation ratios pose near-term risks. Key opportunities include sustained earnings beats and AI initiatives, while risks involve competitive pressures and execution challenges in a volatile market.
Netflix (NFLX) trades at $76.29, up 2.9% in the last session, showing resilience amid recent volatility. The stock exhibits bullish technical signals with strong moving average alignment, though RSI levels suggest potential overbought conditions near-term. Fundamentally, Netflix demonstrates robust growth with Q1 2026 EPS beating expectations at $1.23 versus $0.763, and revenue climbing to $45.18 billion in 2025. Operating cash flow surged to $10.15 billion, underscoring financial health. The company's expansion into advertising and live sports is viewed positively by analysts.
Outlook remains favorable with a consensus price target of $90.45, implying ~19% upside, supported by 64% analyst buy ratings. Key opportunities include ad-tier monetization and global content leadership. Risks involve competitive pressures from streaming rivals, execution on new initiatives, and market sentiment shifts. The stock's current valuation at P/E 23.52 appears reasonable given earnings growth trajectory, but investors should monitor quarterly execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
